Background and Objective There is no available evidence to recommend gonadotropin-releasing hormone (GnRH) analogue-based ovarian suppression versus bilateral salpingo-oophorectomy (BSO) in the adjuvant treatment of early breast cancer, since the two approaches are considered equivalent in terms of oncologic outcome. The role of surgical ovarian ablation has been revitalized based on the advances of minimally invasive surgery, and a better understanding of clinical and molecular basis of hereditary breast/ovarian cancer syndromes. The aim of this study is to analyze the cost-effectiveness of laparoscopic BSO and GnRH analogue administration in patients aged 40-49 years with hormone-sensitive breast cancer. Methods A probabilistic decision tree model was developed to evaluate costs and outcomes of ovarian ablation through laparoscopic BSO, or ovarian suppression through monthly injections of GnRH analogue. Results were expressed as incremental costs per quality-adjusted life years (QALYs) gained. Results Laparoscopic BSO strategy was associated with a lower mean total cost per patient than GnRH treatment, and considering the difference in terms of QALYs, the incremental effectiveness did not demonstrate a notable difference between the two approaches. From the National Health Service perspective, and for a time horizon of 5 years, laparoscopic BSO was the dominant option compared to GnRH treatment; laparoscopic BSO was less expensive than GnRH, €2385 [95% confidence interval (CI) = 2044, 2753] vs €7093 (95% CI = 3409, 12,105), respectively, and more effective. Conclusion Surgical ovarian ablation is more cost-effective than GnRH administration in the adjuvant treatment of hormone-sensitive breast cancer patients aged 40-49 years, and the advantage of preventing ovarian cancer through laparoscopic BSO should be considered.
Introduction
Ovarian ablation through bilateral salpingo-oophorectomy (BSO) has been recognized since 1896 as a valid method of endocrine manipulation in hormone-sensitive advanced breast carcinoma [1] [2] [3] [4] .
Even though there are still debated issues relative to the limited number and quality of studies comparing gonadotropin-releasing hormone (GnRH) analogue-based ovarian suppression versus BSO in the adjuvant treatment of early breast cancer patients [5] [6] [7] , there is no available evidence to recommend medical instead of surgical ovarian ablation since the two approaches are considered equivalent in terms of oncologic outcome [8] . Nonetheless, pharmacological ovarian suppression has progressively replaced BSO over time, because of the potential advantage to avoid surgery-related complications as well as the consequences of irreversible menopause. In this context, current guidelines suggest the use of monthly doses of GnRH analogue for 2-to-3 years in combination with tamoxifen for 5 years, or alternatively, the association of both drugs for 2-to-3 years with subsequent replacement of tamoxifen with an aromatase inhibitor [8, 9] .
Recent results from the SOFT and TEXT randomized Phase III studies in hormone receptor-positive, HER-2-negative breast cancer (BC) patients have provided relevant clinical issues; in particular, the data from the SOFT trial have reported no significantly different 5-year diseasefree survival rates in patients treated with tamoxifen plus GnRH analogue versus tamoxifen alone [10, 11] . On the other hand, in the low-risk subpopulation (women aged [40 years with small and lymph node negative tumors of low-to-intermediate grade) tamoxifen alone can be considered the standard treatment. On the other hand, in a preplanned analysis of patients who remained premenopausal after chemotherapy, and had high-risk features, exemestane plus GnRH was shown to provide longer 5-year BC-free interval compared to tamoxifen plus GnRH (82.5%) and tamoxifen alone (78.0%), thus underlining the need of more individualized approaches according to patient features [10, 11] . In recent years, the role of surgical ovarian ablation has been revitalized based on the advances of minimally invasive surgery, which nowadays provides excellent results in terms of cosmetic outcome, short operating times, hospital stay, and return to normal activity, as well as low rates of complications [12] [13] [14] . Moreover, a better understanding of the clinical and molecular basis of hereditary breast/ovarian cancer syndromes has resulted in a greater awareness by BC patients of their lifetime risk of developing primary ovarian carcinoma [15] [16] [17] [18] . Indeed, ovarian cancer represents one of the most common malignancies among BC survivors, especially when BC diagnosis is done at a younger age [16] ; in particular the observed number of ovarian cancer cases documented among estrogen receptor (ER)-positive BC survivors aged \50 years is, on average, 21% higher compared to the expected number of ovarian cancers in the general population [17] . Since prophylactic BSO has been shown to dramatically reduce (up to 80-90%) the risk to develop ovarian cancer in women endowed with personal/familial risk factors as well as BRCA 1/2 gene mutation [18, 19] , it could represent a valid clinical and cost-effectiveness option in the adjuvant treatment of preand perimenopausal hormone-sensitive BC patients, and an effective strategy for ovarian cancer prevention.
Few studies have already addressed the cost-effectiveness issues of laparoscopic BSO versus GnRH ovarian ablation in pre-and perimenopausal BC patients [20] [21] [22] : evidence has shown the cost-effectiveness superiority of surgical versus medical (i.e. GnRH or tamoxifen) ovarian ablation. However, only one of these studies has applied a decision-tree model and analyzed the results in terms of quality-adjusted life years (QALYs) [21] . Moreover, it has also to be emphasized that, to our knowledge, no formal analysis has investigated in this specific setting, the costeffectiveness performance of the two strategies in terms of prevention of ovarian cancer, a very aggressive disease endowed with intrinsic and treatment-related high levels of morbidity and mortality, with consequently heavy social, and health-care costs.
The aim of this study is to analyze the cost-effectiveness of laparoscopic BSO and GnRH analogue administration in patients aged 40-49 years with hormone-sensitive BC. A decision-tree model has been developed, and results have been expressed in terms of QALYs gained, based on the utilities related to BC outcome, ovarian cancer prevention and treatment outcome.
Methods

Model Structure
A probabilistic decision-tree model was developed in order to evaluate costs and outcomes of ovarian ablation through laparoscopic BSO, or ovarian suppression through monthly injections of GnRH analogue in patients aged 40-49 years with hormone-sensitive BC.
We deliberately chose to focus the attention on the 5-year time horizon, based on the data obtained from the Surveillance, Epidemiology, and End Results Program published by Schonfeld et al [18] ; indeed, this study reported the standardized incidence ratio for the occurrence of a second primary ovarian cancer among ERpositive premenopausal BC patients within 5 years since BC diagnosis. In this context, considering a time horizon of 5 years (short term), the decision-tree model would represent the best choice for simulating the disease evolution without data transformation and assumption needed. In fact, in this case we can apply the risk parameters derived from the two studies without any assumption referred to the transformation of 5-year probabilities in 1 year, or less, lag probability (needed in case of a Markov Model). Furthermore, considering that the data from the literature represent cumulative risks in a 5-year time horizon, Markov Model approach probably would not add information, or significantly change the results, while it complicates the model and adds many assumptions. Figure 1 represents the model structure that simulates natural history of the selected cohort of BC patients proceeding through the different treatment strategies and disease outcomes.
The model was structured considering the possibilities for patients triaged to the two treatment arms to survive or die during a 5-year horizon. If patients survive, the model considers the opportunity to experience BC relapse or survive in health. A second step has considered the risk of developing primary ovarian carcinoma, and the consequent risk of developing ovarian cancer relapse.
For each treatment strategy, costs associated with surveillance and treatment procedures were calculated. A 5-year horizon and National Health System perspective were considered.
The National Health Service (NHS) administers the functions belonging to the Government for the protection of human health, coordination of national healthcare services, veterinary health, protection of health in the workplace, hygiene (including disease prevention) and food safety. The fundamental ideas underlying the NHS are the following: (1) health services should be available to everyone on the basis of need, free of charge, without differentiation or discrimination among citizens and without barriers at the point of use (universalism); (2) the system should be subject to popular democratic control at national, regional, and local level (participation) [23] .
Epidemiological Parameters and Utilities
Epidemiological and clinical estimates were obtained from the available literature; in particular a review of English language literature was performed using PubMed, and Medline by use of the following terms ''breast cancer [TITLE] AND ovarian ablation [TITLE]''.
Efforts have been made to utilize data originated from Phase III trials, or meta-analyses; however, when these data were lacking, data from Phase II trials or clinical experience were used. Criteria for inclusion included year of publication from 2005 to March 2015.
Supplementary Figure 1 shows the flow chart of literature search, and number of selected studies included in the final analysis, according to predefined criteria: (1) we included the full text articles published between 2005 and March 2015, with complete information, and (2) we excluded full text articles focused on selected groups such as specific ethnic groups, different age intervals or populations with other clinical features different from the study population.
Data regarding the 5-year overall survival, and the 5-year relapse-free survival rates after BSO and GnRH were extracted from the literature, thus selecting a minimum and a maximum value and calculating an average. Table 1 summarizes all clinical and epidemiologic parameters that were used to generate the transition probabilities, and shows mean values, and the 95% confidence intervals (95% CIs). Utilities for survival and recurrence were obtained from the available evidences [6, 13, 18, 19, [24] [25] [26] [27] .
The model was calibrated using data on the age-specific (40-49 years) rate of the 5-year BC survival and relapse after BSO or GnRH analogue, and on the incidence of primary ovarian cancer as well as the 3-year probability of ovarian cancer relapse after the two strategies, respectively.
Economic Parameters
All direct medical costs associated with each of the two strategies were compared. Costs of all medical-surgical procedures have been defined on the basis of the so-called ''Diagnosis-Related Group'' (DRG, version 24th) [28] ; in this model, the direct costs have been estimated through the tariffs associated with specific DRG. The 14th DRG system identifies a considerable number of diagnoses associated with hospital admissions, which were selected to be significant and homogeneous both in terms of clinical profile and economic resources absorbed (iso-resources). Therefore, DRGs can be defined as an iso-resources system describing the complexity of the assistance given to patients on the basis of the assumption that similar diseases in similar hospitals are treated with the same level of resources (including any type of drug, materials, and personnel, excluding physicians). This macro-system, aggregating all activities, measures the healthcare provided by hospitals and predicts the relative amount of economic resources needed as a proxy. Therefore, to each specific diagnosis is assigned a reimbursement tariff corresponding to the sum of whole interventions provided.
For each DRG cost, an average score was calculated balanced by the rates specified in the 21-regional resolutions found: Abruzzo, Basilicata, Bolzano, Calabria, Campania, Emilia-Romagna, Friuli Venezia Giulia, Lazio, Liguria, Lombardy, Marche, Molise, Piedmont, Puglia, Sardinia, Sicily, Tuscany, Trento, Umbria, Valle d'Aosta, Veneto.
Estimated economic parameters are presented in Table 2 .
Concerning GnRH analogue, we considered a monthly administration of one drug unit for a maximum period of 36 months in the absence of disease relapse; further details are provided in Supplementary Table 1. For laparoscopic BSO strategy, the DRG 359 has been considered (hysterectomy and/or adnexectomy for nonmalignant conditions, no complications). Further details are reported in Supplementary Table 1. For BC and ovarian cancer management, costs have been estimated based on DRG tariffs, international guidelines, and institutional references (see Table 2 ). In particular for primary ovarian cancer management, we identified the following two therapeutic paths:
(1) radical surgery (generally feasible in 60-70% of cases) followed by six cycles of adjuvant chemotherapy with carboplatin and paclitaxel every 3 weeks; (2) diagnostic laparoscopy or laparotomy with biopsies in patients with unresectable disease at primary effort, followed by For radical surgery, the DRG code 357 has been considered (hysterectomy and/or adnexectomy plus additional surgeries for ovarian carcinoma) (see Supplementary  Table 1 ). For costs of antiblastic chemotherapy, the DRG code 410 was used (antiblastic chemotherapy not associated with a diagnosis of hematological malignancies) (see Table 2 and Supplementary Table 1) .
Final costs were obtained by summing the individual costs weighted by the probability of each event.
Economic and Statistical Analysis
Cost results (€) are reported as the total sum of costs attributable to each patient undergoing each of the two different treatments.
Efficacy results are reported in terms of QALYs [32] gained during the 5-year horizon considered in the model. QALYs were estimated considering the utilities associated to each disease state and weighted considering the transition risks and the time spent in each state. The cost-effectiveness comparison between the different treatment options was expressed as incremental cost-effectiveness ratio (ICER), which corresponds to the result of the cost differences between the two treatments, divided by the differences between their respective efficacy. In the absence of an Italian official threshold, a willingness-topay value of €25,000 to €40,000 per QALY gained was used [33] .
To verify the uncertainty of the model results, a deterministic one-way and probabilistic sensitivity analysis [deterministic safety analysis (DSA) and probabilistic sensitivity assessment (PSA), respectively] was performed [34] Univariate sensitivity analysis was conducted modifying baseline costs and probabilities within the range reported in Tables 1 and 2 . In particular, the following scenarios were investigated: 5-year survival with BSO, primary ovarian cancer with BSO, utility of ovarian cancer, cost of GnRH, cost of BSO, cost of primary ovarian cancer.
PSA provides a useful technique to quantify the level of confidence of a decision maker in drawing conclusions from an economic evaluation [34] .
A probabilistic distribution was associated for cost parameters (gamma distribution) and epidemiological parameters (beta distribution) and 1000 Montecarlo simulation were performed to define Cost-Effectiveness Plan and 95% CI (calculated considering mean and standard deviation derived from the simulations) [35] .
Considering the short time horizon, no discount rates were applied for both costs and outcomes. Two-tailed t test was performed for estimating differences between BSO and GnRH group, and p values \0.05 were considered as statistically significant.
The model and the sensitivity analysis were developed in Microsoft ExcelÒ (Microsoft, Redmond, WA, USA). From the NHS perspective and for a time horizon of 5 years, laparoscopic BSO was the dominant option (more effective and less expensive) compared to GnRH treatment.
Costs associated with ovarian cancer management, accounted for 0.33% of the overall costs estimated for GnRH, and for 0.06% of the costs estimated for BSO (data not shown); therefore, as far as costs of ovarian cancer management only are concerned, BSO resulted in 81% reduction compared to GnRH.
As shown in Table 4 , univariate sensitivity analysis showed a good robustness of the model: indeed, laparoscopic BSO was less expensive and more effective than GnRH in 13 out of 14 possible scenarios analyzed; the exception refers to the case in which the survival probability was 0.80 versus the base case of 0.834.
We performed the cost-effectiveness acceptability curve (CEAC) (Supplementary Figure 2) , but due to the variability in terms of efficacy, and smaller differences in terms of QALYs, the curve decreases when the values of willingness to pay (WTP) increase. After applying probability sensitivity analysis, the model demonstrates that the difference in terms of costs was so wide as to be of important relevance (Fig. 2) ; 99.9% of Monte Carlo simulations estimate the cost of BSO lower than cost of GnRH; number of simulations below the x-axis). However, considering the difference in terms of QALYs, incremental effectiveness did not demonstrate a notable difference between the two approaches (51.0% of Monte Carlo simulations estimated efficacy of BSO higher than GnRH; number of simulations at the right side of y-axis).
Analysis shows that there is an 82.0% probability the BSO strategy is cost-effective at a WTP of €30,000 (82.0% of Monte Carlo simulations are below the red line).
Discussion
This cost-effectiveness analysis showed that laparoscopic BSO is more cost effective than GnRH administration in the adjuvant treatment of BC patients aged 40-49 years. This was confirmed by univariate analysis, which favored laparoscopic BSO in all but one of the scenarios analyzed, thus demonstrating a good robustness of the model. Moreover, probability sensitivity analysis resulted in 82% probability of laparoscopic BSO being more effective than GnRH at a WTP of €30,000.
Although this issue has been addressed by other studies, our analysis seems to provide novel information: in particular it represents the first example of a decision-tree model developed in the context of a European National Health System perspective utilizing the direct costs estimated through the tariffs associated with specific DRGs. Indeed, the only available formal cost-effectiveness analysis of laparoscopic BSO versus medical ovarian suppression in premenopausal BC patients has utilized direct costs obtained from the literature or from hospital billing records in USA [36] . The achievement of the same conclusions, despite the differences in healthcare systems and modalities of cost calculation, further sustain the reliability of current results.
Costs of complications associated with each approach (e.g. peri-operative complications of laparoscopic BSO or GnRH gonadotropin releasing hormone, BSO bilateral salpingo-oophorectomy, ICER incremental cost-effectiveness ratio, QALY quality adjusted life years, CI confidence interval moderate/severe injection site reactions for GnRH) have not been included in the analysis because they were considered as occurring at negligible rates [12] [13] [14] 37] ; conversely, we carefully considered the issues of medical morbidities associated with menopause induction, and planned to focus on the group of hormone-responsive BC patients aged 40-49 years. Besides the advantage to reduce the impact of different cohorts in terms of population heterogeneity, the choice of 40-49-year-olds was made in order to restrict the analysis to patients who were closer to the age of physiologically occurring menopause, who were more likely to better face the anticipated menopause (especially the irreversible one associated with BSO), with its burden of fear of a longer period of estrogen deprivation and related morbidities. As recognized earlier [36] , the implications of emotional distress from surgically induced menopause are generally hardly quantifiable, and are expected to vary across different clinical settings: for instance, in women at high heredo-familial risk of developing breast and ovarian cancer, the unfavorable impact of surgically induced menopause on quality of life is overcome by the decrease of anxiety [19, 38, 39] . On the other hand, the utilities developed in high-risk, but still healthy women, unlikely reflect the utilities of patients who have already faced breast carcinoma, as in our model. Therefore, with the aim to provide individualized counselling, efforts should be made to develop more specific utilities for each clinical setting. Finally, in this specific setting of patients, our study first analyzed the cost-effectiveness of laparoscopic BSO in terms of primary ovarian cancer prevention.
The costs associated with ovarian cancer management contributed to only 0.33% and 0.06% of the overall costs estimated for GnRH and laparoscopic BSO, respectively; this has to be ascribed to the relatively high risk of ovarian cancer development (about 21%) in hormone-sensitive BC patients compared to general population [18] . However, if we consider the costs of ovarian cancer management only, laparoscopic BSO resulted in 81% cost reduction compared to GnRH. Moreover, the ethical implications inherent in the prevention of a very aggressive disease, even in a limited number of patients, adds further value to the choice of surgical approach to ovarian ablation.
Some limitations of the study need to be taken into account: first, the studies selected for the extraction of outcome figures and utilities, although being mainly represented by meta-analyses and large trials, were not so recent, and consequently could not take into account the novel clinical and molecular acquisitions related to the acknowledgement of the key role of BRCA gene system in breast and ovarian cancer natural history [16] . Such information could have intuitively played a role in a better discrimination of hormone-sensitive BC patients at higher or lower risk of ovarian cancer development: for instance, breast tumors with mutation of the BRCA2 gene, which carries a lower risk of ovarian cancer development compared to mutation of BRCA1, are more frequently ER positive [40] .
It is noteworthy that for young women carrying a germ mutation of BRCA1 and BRCA 2 genes, the prophylactic BSO is indicated by the age of 40 or at the end of the reproductive age. This approach would reduce the risk of ovarian cancer by 80-90% and the risk of BC by 50%, with an improvement of global and psychological women's health. In fact, the possible worsening of quality-of-life and endocrine symptoms related to surgical menopause are counterbalanced by the improvement of the anxiety associated with the risk of developing an ovarian malignancy [19, 20, 41] .
Therefore, it should be highlighted that women's indecision to undergo a surgical procedure due to aesthetic effects, complications or functional compromises, has been greatly minimized by the development of modern miniinvasive surgical approaches [42] .
We did not take into consideration the costs related to the management of BC recurrence; however, it has to be acknowledged that treatment options may show an excess of variation in this clinical setting, and sometimes expenses relative to the supportive care/cure are administered outside the hospital, and are not easily quantifiable.
Conclusions
In conclusion, we showed that surgical ovarian ablation is more cost-effective than GnRH administration in the adjuvant treatment of hormone-sensitive BC patients aged 40-49 years.
The advantage of preventing ovarian cancer through laparoscopic BSO should not be underestimated. Despite the reduction of ovarian cancer, management costs contribute minimally to the overall costs.
Within hormone-sensitive BC patients, there is a need to identify those who can be offered surgical ovarian ablation. They should be individualized according to familial risk, reproductive history and have counselling about side effects of anticipated menopause as well as alternative strategies. Indeed, the issues related to prevention of ovarian cancer risk, as well as the potential worsening of quality-of-life due to surgical menopause, represent a very delicate and private aspect influencing a patient's choice; in this context, efforts should be made to identify conditions and provide supportive approaches that can facilitate and support high-risk patients in making their choice. Therefore, regardless of the results from cost-effectiveness analyses, the physician's judgement and patients' preferences still remain the ultimate determinants in the choice of treatments.
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